• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Others

    European Commission Approves Rybrevant & Lazcluze Combo for NSCLC

    GLOBENEWSWIRE

    European Commission Approves Yuvanci For PAH

    GLOBENEWSWIRE

    TAR-200 Shows 84% Complete Response In High-Risk Bladder Cancer

    GLOBENEWSWIRE

    Prophylactic Dexamethasone Reduces Reactions In EGFR-Mutated NSCLC

    GLOBENEWSWIRE

    EC Approves RYBREVANT For EGFR-Mutated Non-Small Cell Lung Cancer

    GLOBENEWSWIRE

    EC Approves BALVERSA For Unresectable Or Metastatic Urothelial Carcinoma

    GLOBENEWSWIRE

    CHMP Recommends RYBREVANT With Chemo For Advanced EGFR-Mutated NSCLC

    GLOBENEWSWIRE

    CHMP Adopts Positive Opinion For BALVERSA To Treat Urothelial Carcinoma

    GLOBENEWSWIRE

    RYBREVANT® With Chemotherapy Approved By European Commission For Lung Cancer

    GLOBENEWSWIRE

    Janssen, Roche lead rankings in blood, breast, lung, and prostate cancer

    FIERCE PHARMA

    IMBRUVICA Shows 10-Year Survival Benefit In First-Line CLL

    GLOBENEWSWIRE

    IMBRUVICA Plus Venetoclax Shows Sustained Benefit In CLL

    GLOBENEWSWIRE

    TALVEY Shows Durable Responses In R R Multiple Myeloma

    GLOBENEWSWIRE

    TECVAYLI Shows Durable Responses In Relapsed/Refractory Myeloma

    GLOBENEWSWIRE

    CARVYKTI Improved PFS, Deepened Responses In High-Risk Multiple Myeloma

    GLOBENEWSWIRE

    EC Approves Carvykti for RRMM| Int`l Myeloma Foundation

    PRESS RELEASE

    Johnson & Johnson submits application to the EMA for DARZALEX

    GLOBENEWSWIRE

    Janssen Submits Application to EMA Seeking Approval of RYBREVANT

    PRESS RELEASE

    Additional manufacturing site for COVID-19 Vaccine Janssen

    EMA

    FDA finalizes guidance on metastasis-free survival as an endpoint

    RAPS

    Janssen-Cilag seeks EMA authorisation for Covid-19 vaccine candidate

    PHARMACEUTICAL-TECHNOLOGY

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.